drugset / Trial / NCT01552980
Efficacy and Safety Study of a Modified SOX Regimen in First-Line Treatment of Unresectable Gastric Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, phase II study to evaluate the efficacy and safety of a modified regimen of oxaliplatin and S-1 on unresectable gastric adenocarcinoma in the first-line therapy.
Timeline
- Start
- 2012-03
- Primary completion
- 2013-08
- Completion
- 2014-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | — |
| Subject | S-1 | Small molecule | 40 mg/m2 | — |